What Co-Dafalgan (Acetaminophen, Codeine) Treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains where short-term symptomatic assistance is needed to address episodes of heightened discomfort. It is applied in scenarios where additional management of pain is required for moderate symptoms.

This combination is relevant for easing symptoms related to physical discomfort and systemic imbalance, and is used to manage manifestations such as moderate tension headaches, backache, muscle pain, and severe period pain. It is often used in acute post-traumatic and post-procedural contexts where symptoms create noticeable temporary functional strain.

“The medicine is relevant when symptoms become temporarily overwhelming, contributing to improved comfort during periods of heightened symptoms.”

This medication contributes to easing the overall symptom load and assists with maintaining functional stability during difficult episodes.

Quick Fact: Symptom Categories
Relevant For	Pain that interferes with daily functioning
Dual Symptom Focus	Pain and fever
Use Context	Acute or episodic symptomatic episodes

Regulatory References

1. Acetaminophen and Codeine: MedlinePlus Drug Information

Who Can and Cannot Use Co-Dafalgan (Acetaminophen, Codeine)?

Eligibility for Co-Dafalgan is strictly defined by regulatory authorities based on age, physiological status, and underlying medical conditions. The medicine is contraindicated and must not be used in several defined populations.

---

Absolute Contraindications

Category	Non-Eligibility Status
Age	Children younger than 12 years of age are prohibited from using this medicine.
Pediatric Surgery	Adolescents younger than 18 years following tonsillectomy and/or adenoidectomy for obstructive sleep apnoea are contraindicated.
Physiological Status	Breastfeeding women are contraindicated due to the transfer of codeine into breast milk.
Metabolism	Individuals known to be ultra-rapid metabolizers of codeine (CYP2D6 polymorphism) must not use this product.
Organ Function	Patients with severe hepatic insufficiency or pre-existing severe liver disease.
Acute Conditions	Patients with significant respiratory depression or acute or severe bronchial asthma in an unmonitored setting.

---

Conditional or Restricted Use

Use is restricted or requires special caution in populations with certain comorbidities or physiological states. This includes patients with severe renal impairment, conditions that cause increased intracranial pressure, hypothyroidism, or a history of opioid dependence. Long-term use in pregnant women is not recommended due to the potential risk of Neonatal Opioid Withdrawal Syndrome. Older patients may require lower initial doses and careful monitoring.

Interactions with other medicines and products

The official regulatory profile for this fixed-dose combination highlights specific drug-drug, drug-substance, and population-based interaction constraints. The following statements describe the interaction patterns and restrictions strictly based on government regulatory documentation.

High-Risk and Contraindicated Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration is formally contraindicated. A mandatory 14-day separation period is required after the MAOI is discontinued before starting this medicine.
• Alcohol and CNS Depressants: Co-administration with ethanol or other Central Nervous System (CNS) Depressants (e.g., benzodiazepines, general anesthetics) results in a severe additive pharmacodynamic effect, documented to increase the risk of profound sedation and respiratory depression.
• Serotonergic Drugs: Concomitant use with other serotonergic agents may result in the development of serotonin syndrome.

Pharmacokinetic and Exposure Modification

• CYP2D6/CYP3A4 Modulators: Pharmacokinetic interactions occur via the Cytochrome P450 enzyme system. Co-administration with CYP2D6 inhibitors (e.g., paroxetine) can reduce the active metabolite's plasma concentration, officially leading to reduced analgesic efficacy. The addition or discontinuation of CYP3A4 modulators (e.g., certain antibiotics, antifungals) also alters codeine exposure levels.
• Genetic and Organ Status: Official labeling includes constraints for CYP2D6 Ultra-Rapid Metabolizers, who are documented to have significantly higher active metabolite exposure. Caution is also advised for patients with severe hepatic or renal impairment due to potentially slower clearance.

The mechanism of action for Co-Dafalgan involves a dual-pathway mechanistic engagement, leveraging the distinct biological targets of its two components to regulate overactive physiological processes.

Acetaminophen: Central Inhibition of Prostaglandin Synthesis

The acetaminophen component acts primarily within the Central Nervous System (CNS), modulating Cyclooxygenase (COX) enzymes to limit the synthesis of prostaglandins. These signaling mediators are critical for raising the body's temperature set point and contributing to nociceptive signaling. This effect alters the elevated temperature set point and lowers the impact of excessive central mediator activity.

---

Codeine: mu-Opioid Receptor Agonism

Codeine acts as a prodrug, being converted to morphine, which then binds to mu-opioid receptors ( MOR) in the CNS. Activation of these receptors initiates signaling sequences that suppress the transmission of nociceptive input and modulate central affective signaling. This mechanism engages key regulatory systems to modulate activity within the targeted neural pathways.

---

Dual-Action Synergistic Modulation

The drug engages mechanisms that influence both mediator synthesis (acetaminophen) and signal transmission/perception (codeine), resulting in a synergistic mechanistic interaction. By modulating activity within these distinct receptor and enzyme systems simultaneously, the combination is capable of influencing multiple points in the physiological cascade.

The administration of the Acetaminophen and Codeine combination focuses on controlled oral use, precise dosing intervals, and limited duration. The medicine is exclusively intended for oral administration. Standard adult regimens specify a single dose of 1 to 2 tablets, typically containing 500 mg Acetaminophen and 30 mg Codeine, with a minimum of 4 to 6 hours required between each dose. The total daily intake of the Acetaminophen component from all sources must not exceed 4 grams per 24 hours. Administration is flexible regarding meals, as the medicine can generally be taken with or without food. However, preparation is form-specific: film-coated tablets must be swallowed whole with liquid, while effervescent tablets must be fully dissolved in water prior to ingestion.

The combination product is designated for short-term use only, with treatment often restricted to a maximum duration of 3 days for acute symptoms. The instruction is to utilize the lowest effective dose for the shortest necessary duration. Specific dosing modifications are required for certain patient populations. The required interval between doses must be extended for individuals with renal or hepatic impairment to account for reduced drug clearance. Furthermore, the use of this combination is contraindicated in children younger than 12 years of age. Concurrent use of any other product containing Acetaminophen is avoided to prevent the maximum daily limit from being surpassed.

Co-Dafalgan (Acetaminophen,Codeine): Recent Clinical Evidence

Clinical evidence regarding the use of the Acetaminophen-Codeine combination primarily focuses on its effectiveness in acute, moderate to severe pain. Codeine, a weak opioid, requires conversion into morphine by the liver enzyme CYP2D6 to provide pain relief. Because individual metabolic rates vary, the analgesic effect can be unpredictable.

---

Acute Pain Management Studies

Meta-analyses of single-dose trials, often involving postoperative pain, have examined the analgesic effect of the combination compared to its individual components or placebo. These studies suggest that the addition of codeine to acetaminophen may provide an incremental benefit in pain relief for some patients.

• One large review of acute postoperative pain found that higher doses of the combination (e.g., 1000 mg acetaminophen plus 60 mg codeine) were associated with a statistically significant increase in the proportion of participants achieving at least 50% pain relief over a four-to-six-hour period, compared to placebo.
• The combination has also been explored in acute musculoskeletal pain, where some comparative studies found it offered analgesia similar to that provided by other opioid-acetaminophen combinations, although with varying side effect profiles.

---

Safety and Comparative Data

While studies may show modest additional efficacy, they also consistently report a higher rate of adverse effects compared to acetaminophen alone. These typically include mild to moderate side effects such as drowsiness, nausea, and constipation. Some evidence suggests that non-opioid combinations, such as acetaminophen and ibuprofen, may provide similar pain relief efficacy with a lower incidence of side effects.

• Risk Factors in Codeine Use: Regulatory bodies have noted the risk of life-threatening respiratory depression in ultra-rapid metabolizers of codeine. Due to safety concerns, codeine use is generally contraindicated in children under 12 years of age and those under 18 following tonsillectomy or adenoidectomy.

Key Studies & References

1. Tonsillectomy in Children: Update to Guidelines for Treating and Managing Care
2. Annotation of FDA Label for codeine and CYP2D6 (Ultra-Rapid Metabolism and Respiratory Depression Risk)

Common questions about Co-Dafalgan (Acetaminophen,Codeine) (FAQ)

---

Q: Is Co-Dafalgan considered a strong pain reliever compared to over-the-counter options?

Official information describes this medicine for the symptomatic relief of moderate pain when single-agent, non-opioid analgesics are insufficient. Studies suggest the combination is noted to provide a level of relief greater than that provided by either compound when administered in isolation. The medicine is positioned as a comprehensive strategy for discomfort that requires stepped-up management.

---

Q: How is Co-Dafalgan different from taking regular acetaminophen (paracetamol) alone?

Co-Dafalgan is a fixed-dose combination product designed to provide dual-action pain relief. It uses acetaminophen to reduce pain and fever, while the codeine component acts on the Central Nervous System (CNS) to dampen pain signals. This synergistic mechanism is intended to result in a level of relief that is greater than that offered by acetaminophen alone.

---

Q: What is the difference between Co-Dafalgan and other combination medicines that contain codeine?

Studies have compared the analgesic effect of the acetaminophen-codeine combination to other opioid-containing pain medications. Evidence indicates that this combination offered analgesia similar to that provided by other opioid combinations. However, official documents note that the specific composition may result in different side effect profiles compared to other products.

---

Q: Can I take Co-Dafalgan with anti-anxiety medicine?

Official regulatory warnings advise against combining this medicine with other Central Nervous System (CNS) Depressants, a category which includes certain anti-anxiety medications like benzodiazepines. Official documents describe that co-administration can result in an additive effect, documented to increase the risk of profound sedation and respiratory depression.

---

Q: What information is available regarding the use of Co-Dafalgan during pregnancy?

Official guidelines advise that long-term use of this medicine is not recommended during pregnancy. This caution is due to the potential risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

---

Q: Does Co-Dafalgan affect a person's ability to drive, operate machinery, or perform tasks requiring full alertness?

Regulatory documents consistently list common side effects that affect the Central Nervous System (CNS), such as drowsiness, lightheadedness, and sedation. These effects are generally recognized as potentially impairing a person's ability to drive or safely operate machinery.

---

Q: Can Co-Dafalgan potentially make symptoms of existing anxiety or depression feel worse?

The codeine component of the drug modulates central affective signaling. Official regulatory warnings highlight that co-administration with other serotonergic agents can potentially lead to the development of serotonin syndrome, which involves serious changes in mental status.

---

Q: What should a patient know if their Co-Dafalgan tablet is scored (has a line across it)?

Regulatory patient information often specifies how different tablet forms should be handled. While film-coated tablets are typically swallowed whole, instructions for scored tablets often indicate they can be divided to facilitate administration. It is important to check the instructions specific to the product's formulation.

---

Q: Does Co-Dafalgan also help with reducing inflammation?

Official documentation classifies this product as an analgesic (pain reliever) and antipyretic (fever reducer). The medicine is not described in official regulatory documents as possessing anti-inflammatory properties.

---

Q: Are there different strengths of Co-Dafalgan available to patients?

Regulatory regimens for the acetaminophen and codeine combination often exist in different strengths, depending on the prescribing country and indication. These variations typically involve different amounts of the codeine component combined with a standard dose of acetaminophen.

---

Q: Can Co-Dafalgan be obtained without a prescription in certain countries?

The codeine component dictates the drug's legal classification and availability. In some jurisdictions, lower strengths of codeine combinations are classified such that they can be obtained without a prescription, while higher strengths require a prescription.

---

Q: Is it possible to experience a 'high' or euphoric feeling from Co-Dafalgan?

As an opioid, the codeine component acts on receptors in the Central Nervous System (CNS) that affect pain perception and mood. This mechanism forms the basis for the medicine’s formally documented risks of abuse and misuse.

---

Q: How quickly does Co-Dafalgan typically start to provide pain relief?

Pharmacokinetic data available in regulatory documents suggest the time to reach maximum plasma concentration (Tmax) for the active components is usually within 1 to 2 hours of taking the medicine. This time frame is often cited in relation to the onset of the medicine's effect.

---

Q: What is the expected duration of pain relief after taking Co-Dafalgan?

Official regulatory dosing protocols specify a minimum of 4 to 6 hours between each dose. This interval aligns with the duration of the analgesic effect examined in clinical pain relief trials.

---

Q: Are there specific dietary restrictions or foods that interact with Co-Dafalgan?

The official administration instructions describe the intake of the medicine as generally flexible regarding meals. The medicine can typically be taken either with or without food.

---

Q: Can common herbal supplements interfere with the effectiveness or safety of Co-Dafalgan?

Regulatory documents warn of pharmacokinetic interactions via the CYP450 enzyme system, which processes the medicine in the body. Herbal supplements that modulate this enzyme system may alter codeine exposure levels and potentially impact efficacy or safety.

---

Q: Is Co-Dafalgan considered safe for people who are 65 years of age and older?

Official constraints advise that older patients may require special attention and careful monitoring due to potential differences in drug clearance. This often leads to recommendations for lower starting doses.

---

Q: What is the guidance for people with a personal or family history of substance use when considering Co-Dafalgan?

Official guidelines advise special caution for patients with a history of opioid dependence due to the formally documented risks of addiction, abuse, and misuse associated with the codeine component.

---

Q: Where can patients find the official regulatory documents (e.g., SmPC or DailyMed) for Co-Dafalgan?

Official information is made public and maintained by government authorities. Patients can typically find documents such as the Summary of Product Characteristics (SmPC) or the full prescribing information on official websites like the FDA's DailyMed, the MHRA's Compendium, or the EMA's public portals.

---

Q: How does the legal classification of codeine affect its availability and prescribing in different countries?

The classification of codeine as a weak opioid determines the product's regulatory schedule and controls. This affects its availability, with some countries permitting non-prescription access for specific low-strength versions of the medicine.

---

Q: Why have regulatory bodies recently changed the recommendations for codeine use in certain populations?

Changes were driven by critical safety findings, particularly the risk of life-threatening respiratory depression in individuals who are ultra-rapid metabolizers of codeine. This led to specific contraindications, such as prohibiting its use in children and certain post-operative pediatric patients.

---

Q: Why is Co-Dafalgan sometimes mentioned as a treatment for coughs?

The codeine component is listed in some regulatory documents and drug class descriptions as an antitussive (cough suppressant). While this is a known pharmacological effect, it is not the primary stated use or official indication for this combination pain product.

---

Q: Is it true that taking this medicine can sometimes cause confusion or disorientation?

The official safety profile lists several Central Nervous System (CNS) effects, including drowsiness, lightheadedness, and sedation. These documented effects may be associated with an impact on concentration and mental clarity.

---

Q: Is Co-Dafalgan commonly used after dental surgery?

Clinical evidence and studies examining the analgesic effect of the combination frequently involve trials conducted in the context of postoperative pain. The medicine is therefore studied and used as an option for managing pain following surgical procedures.

---

Q: Are there known issues or warnings regarding the use of Co-Dafalgan in patients with glaucoma?

Official restrictions and warnings advise caution for patients with medical conditions that cause increased intracranial pressure. Glaucoma is noted as a condition that falls under this category.

---

Q: Is there a possibility that Co-Dafalgan could cause a false positive result on a standard drug test?

Yes. The codeine component is metabolized into morphine in the body, which is chemically similar to other opioid compounds. Its presence is known to result in a positive screening test for opioids.

---

Q: How does Co-Dafalgan affect sleep quality?

The medicine's official safety profile lists strong Central Nervous System (CNS) depressant effects such as drowsiness, lightheadedness, and sedation. These effects may alter or impact the overall quality of sleep.

How to Store and Dispose of Acetaminophen and Codeine Products

Official regulatory guidelines mandate specific storage and disposal procedures for this combination medicine to ensure stability and security.

---

Required Storage Conditions

The medication must be stored securely, out of the sight and reach of children, and in a location that prevents unauthorized access. Storage is required at controlled room temperature, typically not above 25 C. The product must be kept in its original container, which must be tightly closed, and protected away from direct light, excess heat, and moisture. It is mandatory to keep the medicine from freezing.

Official Disposal Instructions

Unused or expired product should be disposed of promptly. The preferred method is an official drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an unappealing substance (e.g., dirt) and sealed in a container for the household trash. All personal information must be removed from the packaging before disposal. Do not flush the medication unless specifically instructed by the label.